Skip to content
← Survival collections

CANCER EVIDENCE

5-Year Survival

70 published cancer groups · 65,440 source series. Choose a group to explore its populations.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Source table

Published values for each cancer group are on that group page. This release supplies the source and dates.

Source
SEER
Table
5-Year Survival
Data submission
November 2025 submission
Application release
Updated
June 22, 2026
Acquired

Acute Lymphocytic Leukemia (ALL)

240 source series

→

Acute Monocytic Leukemia (AML-M5)

240 source series

→

Acute Myeloid Leukemia (AML)

240 source series

→

Adenocarcinoma of the Esophagus

1,200 source series

→

Adenocarcinoma of the Lung and Bronchus

1,200 source series

→

All Cancer Sites Combined

240 source series

→

Anus, Anal Canal & Anorectum

1,200 source series

→

Bones and Joints

1,200 source series

→

Brain and Other Nervous System

1,200 source series

→

Breast

800 source series

→

Cervix Uteri

400 source series

→

Chronic Lymphocytic Leukemia (CLL)

240 source series

→

Chronic Myeloid Leukemia (CML)

240 source series

→

Chronic Myelomonocytic Leukemia (CMML)

240 source series

→

Chronic myeloproliferative disorders (CMD)

240 source series

→

Colon (including Appendix)

1,200 source series

→

Colon and Rectum (excluding Appendix)

1,200 source series

→

Colon and Rectum (including Appendix)

1,200 source series

→

Corpus and Uterus, NOS

400 source series

→

Diffuse Astrocytoma and Anaplastic Astrocytoma of the Brain and ONS

1,200 source series

→

Embryonal Tumors of the Brain and ONS

1,200 source series

→

Esophagus

1,200 source series

→

Eye and Orbit

1,200 source series

→

Floor of Mouth

1,200 source series

→

Follicular Subtype of the Thyroid

1,200 source series

→

Gallbladder

1,200 source series

→

Glioblastoma of the Brain and ONS

1,200 source series

→

Gum & other mouth

1,200 source series

→

Hodgkin Lymphoma

1,200 source series

→

HR-/HER2- Breast Cancer (Female only)

400 source series

→

HR-/HER2+ Breast Cancer (Female only)

400 source series

→

HR+/HER2- Breast Cancer (Female only)

400 source series

→

HR+/HER2+ Breast Cancer (Female only)

400 source series

→

Kaposi Sarcoma

1,200 source series

→

Kidney

1,200 source series

→

Kidney and Renal Pelvis

1,200 source series

→

Large Cell Carcinoma of the Lung and Bronchus

1,200 source series

→

Larynx

1,200 source series

→

Leukemia

240 source series

→

Lip

1,200 source series

→

Liver and Intrahepatic Bile Duct

1,200 source series

→

Lung and Bronchus

1,200 source series

→

Melanoma of the Skin

1,200 source series

→

Meningioma of the Brain and ONS

1,200 source series

→

Mesothelioma

1,200 source series

→

Myelodysplastic syndromes (MDS)

240 source series

→

Myeloma

1,200 source series

→

Non-Hodgkin Lymphoma

1,200 source series

→

Oral Cavity and Pharynx

1,200 source series

→

Oropharynx & Tonsil

1,200 source series

→

Other Glioma of the Brain and ONS

1,200 source series

→

Ovary

400 source series

→

Pancreas

1,200 source series

→

Papillary Subtype of the Thyroid

1,200 source series

→

Prostate

400 source series

→

Rectum

1,200 source series

→

Renal Pelvis

1,200 source series

→

Salivary Gland

1,200 source series

→

Small cell carcinoma of the Lung and Bronchus

1,200 source series

→

Small Intestine

1,200 source series

→

Soft Tissue including Heart

1,200 source series

→

Squamous Cell Carcinoma of the Esophagus

1,200 source series

→

Squamous Cell Carcinoma of the Lung and Bronchus

1,200 source series

→

Stomach

1,200 source series

→

Testis

400 source series

→

Thyroid

1,200 source series

→

Tongue

1,200 source series

→

Urinary Bladder (Invasive & In Situ)

1,440 source series

→

Vagina

400 source series

→

Vulva

400 source series

→
5-Year Survival · SEER cancer survival | Triangle